From the Guidelines
The starting dose of Vyvanse (lisdexamfetamine) is 20-30 mg orally once daily in the morning. According to the most recent and highest quality study available 1, the usual starting dose for lisdexamfetamine is between 20-30 mg po qam.
Key Considerations
- The dose may be titrated by increasing it by 10 mg weekly to a maximum of 70 mg daily, as needed and as tolerated by the patient.
- It is essential to individualize the dosing based on the patient's response and tolerance, considering factors such as renal impairment or potential interactions with other medications.
- The medication should be taken in the morning, with or without food, and the capsule can be swallowed whole or opened and mixed with water or yogurt if swallowing is difficult.
Important Details
- Lisdexamfetamine is a prodrug that is converted to dextroamphetamine, and there is limited published information on its use in pregnancy and breastfeeding.
- As with any medication, it is crucial to weigh the potential benefits against the potential risks and to monitor patients closely for any adverse effects. Given the information from the study 1, it is clear that the starting dose of Vyvanse should be between 20-30 mg, and any adjustments should be made based on the individual patient's needs and response to the medication.
From the FDA Drug Label
2.3 Dosage for Treatment of ADHD The recommended starting dosage in adults and pediatric patients 6 years and older is 30 mg once daily in the morning. 2.4 Dosage for Treatment of Moderate to Severe BED in Adults The recommended starting dosage in adults is 30 mg once daily to be titrated in increments of 20 mg at approximately weekly intervals to achieve the recommended target dose of 50 mg to 70 mg once daily.
The starting dose of Vyvanse is 30 mg once daily in the morning for both ADHD and moderate to severe BED in adults, and for ADHD in pediatric patients 6 years and older 2.
From the Research
Starting Dose of Vyvanse
- The starting dose of Vyvanse (lisdexamfetamine) is not explicitly stated in the provided studies.
- However, according to the study 3, LDX is a long-acting oral prodrug stimulant, and its pharmacological action involves blocking norepinephrine and dopamine reuptake into presynaptic neurons.
- The study 4 mentions that LDX was administered up to 70 mg/day for 5 weeks in a clinical trial.
- Another study 5 compared the efficacy of LDX with other medications, including mixed amphetamine salts and methylphenidate, but does not provide information on the starting dose.
- It is essential to consult the prescribing information or a healthcare professional for the recommended starting dose of Vyvanse, as it may vary depending on the individual patient's needs and medical history.
Available Information on Vyvanse Dosage
- The study 4 provides information on the dosage of LDX used in a clinical trial, which was up to 70 mg/day.
- However, this information may not be directly applicable to all patients, and the starting dose may need to be adjusted based on individual factors.
- The study 5 mentions that LDX has a high effect size in reducing ADHD symptoms, but does not provide information on the starting dose.
- The study 6 discusses the safety profiles of various medications, including LDX, but does not provide information on the starting dose.
Limitations of Available Information
- The provided studies do not explicitly state the starting dose of Vyvanse.
- The information on dosage is limited to a specific clinical trial 4 and may not be generalizable to all patients.
- It is crucial to consult the prescribing information or a healthcare professional for the recommended starting dose of Vyvanse, as it may vary depending on individual patient factors.